Journal
ADVANCED SYNTHESIS & CATALYSIS
Volume 361, Issue 11, Pages 2421-2432Publisher
WILEY-V C H VERLAG GMBH
DOI: 10.1002/adsc.201900424
Keywords
biocatalysis; enzyme catalysis; industrial chemistry; sustainable chemistry
Categories
Funding
- European Community
- EFPIA companies [115360]
- Strategic Long Larger (sLoLa) Grant Rapid Evolution of Enzymes and Synthetic Micro-organisms for the Development of Industrial Biocatalysts
- BIOCATNET NIBB (BBSRC) [BB/L013649/1]
- BBSRC [BB/K00199X/1]
- BBSRC [BB/L013649/1] Funding Source: UKRI
Ask authors/readers for more resources
Biocatalysis over the past few years has matured into an essential tool for modern, cost effective and sustainable pharmaceutical manufacturing. While some reaction classes are well established, and may even be the option of first intent, other more recently discovered enzyme classes are being rapidly developed both in academia and industry. Notwithstanding this, there are further promising enzymes that require further investment and investigation to allow their future industrial use. We here outline GSK's perspective on the current status of biocatalysis for pharmaceutical manufacturing and provide our views on areas of significant potential.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available